Table 2.
Summary of demographic and clinical characteristics for eyes with CNV due to AMD and WDS
| AMD | WDS | P-value | |
|---|---|---|---|
|
| |||
| Age (years) | 77.3±8.1 | 58.3±11.3 | 0.001 |
| % female | 64% (7/11) | 83% (5/6) | 0.42 |
| % OD | 45% (5/11) | 67% (4/6) | 0.40 |
| % Zeiss | 36% (4/11) | 0% (0/6) | 0.10 |
| Number of prior injections | 16.2±9.7 | 11±13.5 | 0.37 |
| Months since last injection | 12.7±21.2 | 2.25±2.6 | 0.25 |
| LogMAR VA | 0.32±0.26 | 0.27±0.16 | 0.43 |
| % with SRF | 64% (7/11) | 67% (4/6) | 0.90 |
| % with prior PDT | 27% (3/11) | 17% (1/6) | 0.65 |
| % CNV Type 1 | 73% (8/11) | 17% (1/6) | 0.03 |
| CNV area (mm2) | 2.79±1.80 | 0.56±0.32 | 0.01 |
| CNV vessel density | 0.44±0.09 | 0.46±0.09 | 0.71 |
Abbreviations: AMD, age-related macular degeneration; CNV, choroidal neovascularization; logMAR VA, logarithm of the minimum angle of resolution visual acuity; PDT, photodynamic therapy; SRF, subretinal fluid; WDS, white dot syndromes.